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Antimetabolite inhibitors of de novo purine and pyrimidine
synthesis are used extensively in cancer chemotherapeutic regimes
(Schilsky, 1992). In particular, inhibition of thymidylate synthase
(TS) is an attractive target for antimetabolite chemotherapy
because thymine is the only nucleobase found exclusively in DNA
and TS is a key enzyme, possibly the rate-limiting step, in DNA
synthesis. One locus of action of 5-fluorouracil (5-FU), which is
widely used for the treatment of colorectal, breast and head-and-
neck cancer, is TS inhibition following its intracellular conversion
to 5-FdUMP. CB3717 (N10-propargyl-5,8-dideazafolate) was the
first selective antifolate inhibitor of TS to be developed (Jones et
al, 1981), and in early clinical trials with CB3717 promising thera-
peutic activity was reported (Calvert et al, 1986). More recently,
a number of antifolate TS inhibitors have been developed, i.e.
raltitrexed, nolatrexed, MTA, AG 331, BW 1843 U89 and
ZD9331, and activity has been observed against a broad range of
tumours in a number of clinical trials with these agents (Rustum
et al, 1997).
Inhibition of TS results in the depletion of intracellular dTTP
and, as a result of elevated dUMP levels, an accummulation of
dUTP. This nucleotide pool imbalance contributes to DNA strand
breakage and cell death (Curtin et al, 1991). Salvage of extracel-
lular thymidine, mediated by nucleoside transport and subsequent
phosphorylation by thymidine kinase, restores thymidylate pools
and hence limits the activity of TS inhibitors (Jackman et al,
1984). A number of factors may promote utilization of the salvage
pathway by tumours, for example, Weber (1983) has demonstrated
that the activities of the enzymes involved in nucleoside salvage
can exceed those of the de novo pathway for nucleotide synthesis
in a variety of tumours. Furthermore, resistance to antimetabolities
mediated by nucleoside salvage may increase with malignancy
(Fox et al, 1991; Kinsella and Harran, 1991). In addition, release
of nucleic acids from dead cells may result in high local concen-
trations of salvageable nucleosides and bases in tumours.
Salvage of pre-formed nucleosides is dependent on uptake
across the plasma membrane into the cell. At physiological nucle-
oside concentrations the principal mode of nucleoside uptake is
via the es and ei equilibrative carriers, described as such on the
basis of their sensitivity (es) or insensitivity (ei) to the transport
inhibitor nitrobenzylmercaptopurine riboside (NBMPR). The
cardiovascular and antiplatelet drug, dipyridamole, inhibits both es
and  ei carriers, thereby blocking the uptake of nucleosides for
salvage. Dipyridamole has been used successfully in vitro, and to a
limited extent in animal studies, to increase the activity of a range
of antimetabolites (reviewed in Goel and Howell, 1992). In addi-
tion to preventing thymidine uptake, dipyridamole also enhances
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the cytotoxicity of TS inhibitors by preventing the efflux of
deoxyuridine, leading to a greater accumulation of dUTP (Curtin
et al, 1991). Similarly, potentiation of 5-FU cytotoxicity by dipyri-
damole may be mediated not only through inhibition of the uptake
of thymidine for salvage, but also by the inhibition of deoxyuri-
dine and fluorodeoxyuridine efflux, leading to higher intracellular
dUMP, FdUMP and FdUTP concentrations (Grem and Fisher,
1985, 1989).
Despite these promising in vitro data with antimetabolite/dipyri-
damole combinations, improved therapy in patients has not been
achieved. For example, although some phase I studies suggested
an enhancement of 5-FU and methotrexate activity by combina-
tion with dipyridamole (reviewed in Schmoll et al, 1990), in phase
II and III trials the combination with dipyridamole did not improve
the antitumour activity of methotrexate or 5-FU (Wadler et al,
1987; Köhne-Wömpner et al, 1989). The discrepancy between the
clinical and preclinical results obtained with dipyridamole may be
due to the avid binding of the drug to a1-acid glycoprotein (AGP),
(Mahony et al, 1982), an acute phase protein that is elevated in the
plasma of cancer patients. In two studies of patients receiving the
maximum tolerated dose of dipyridamole peak total plasma
concentrations of dipyridamole of 12 mM and 16 mM were achieved
(Willson et al, 1988; Budd et al, 1990), concentrations which
should have been sufficient to prevent nucleoside transport on the
basis of in vitro data; however, the free plasma concentration of
dipyridamole was only 27 nM and 38 nM in these studies, which is
insufficient to enhance antimetabolite activity in vitro. In agree-
ment with the clinical data, physiological levels of AGP have also
been shown to prevent the potentiation of CB3717 growth inhibi-
tion by dipyridamole in vitro (Curtin et al, 1989).
On the basis of in vitro data it should be possible to use nucleo-
side transport inhibitors to enhance the clinical activity of TS
inhibitors, provided the limitations of AGP binding can be over-
come. The aim of the studies described here was to investigate the
effect of novel dipyridamole analogues on the in vitro growth
inhibitory activity of TS. Two antifolate TS inhibitors were
selected for study: the classical antifolate, CB3717 (N10-pro-
pargyl-5,8-dideazafolic acid), and the non-classical antifolate TS
inhibitor, nolatrexed (AG337, Thymitaq, 3,4-dihydro-2-amino-
6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride)
(Webber et al, 1996). In addition, potentiation of the cytotoxicity
of 5-FU was investigated. Data for selected dipyridamole
analogues that are potent inhibitors of thymidine transport, even
in the presence of AGP, are presented. Studies with NU3026,
NU3059 and NU3060 demonstrated that the degree of enhance-
ment of growth inhibition by TS inhibitors was dependent on the
potency of the compounds as inhibitors of thymidine transport. A
further inhibitor, NU3076, was identified, which was more potent
Table 1 Inhibition of thymidine uptake by novel dipyridamole analogues in the presence or absence of 5 mg ml–1 AGP
Inhibitor concentration
Compound Structure 1 mM 10 mM 10 mM + AGP IC50
b (mM)
Dipyridamole 80 ± 8a 99 ± 2 13 ± 12 0.36,
(26) (84) (27)d,e 0.37
2,6-bis-(diethanolamino)-4,8-
di-piperidino-
pyrimidopyrimidine
NU3026 (RR)c 47 ± 5 87 ± 8 62 ± 12 1.2,
(6) (15) (8)d 1.1
2,6-di-(2,2-dimethyl-1,3-
dioxolan-4-yl)-methoxy-
4,8-di-piperidinopyrimido-
pyrimidine
NU3059 38 ± 17 87 ± 7 67 ± 17 1.9 ± 1
(15) (26) (5)d (5)
2,6-bis-(2,3-dimethoxypropoxy)-
4,8-di-piperidino-
pyrimidopyrimidine
NU3060 29 ± 15 86 ± 11 43 ± 8 2.1 ± 0.7
(12) (27) (9)d (3)
2,6-bis[N,N-di(2-methoxy)ethyl]-
4,8-di-piperidino-
pyrimidopyrimidine
Data are individual values or mean ± s.d. for the number of observations given in parenthesis. aData are the % inhibition of thymidine uptake obtained in the
absence or presence of 5 mg ml–1 AGP. bIC50 values for inhibition of thymidine uptake in the absence of AGP (calculated from a point-to-point curve using
GraphPad PrismTM software). cThe (S,S)- and (R,S)-isomers showed similar potency. dSignificantly different from value obtained in the absence of AGP
(unpaired Student’s t-test). eNot significantly different from zero.1740 NJ Curtin et al
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than dipyridamole, active in the presence of AGP and able to
potentiate both nolatrexed and 5-FU cytotoxicity.
MATERIALS AND METHODS
Drugs
CB3717 (a gift from Zeneca Pharmaceuticals, Alderley Park, UK)
was dissolved in 0.15 M sodium hydrogen carbonate and stored at
4°C. Nolatrexed (a gift from Agouron Pharmaceuticals Inc, San
Diego, USA), 5-FU and dipyridamole (Sigma Chemical Co, Poole,
UK), NU3026, NU3059, NU3060 and NU3076 (synthesized in the
Department of Chemistry, University of Newcastle upon Tyne,
UK; for structures see Tables 1 and 2) were dissolved in dimethyl
sulphoxide (DMSO) and stored at –20°C. All other chemicals
were obtained from Sigma unless stated otherwise.
Cell culture
Murine leukaemia L1210 cells were used because their nucleoside
transport characteristics have been well defined (Crawford et al,
1990). Cells were maintained as exponentially growing cultures
(< 8 ´ 105 cells ml–1) in RPMI-1640 medium supplemented with
10% (v/v) fetal calf serum (Sigma), at 37°C in an atmosphere of
5% carbon dioxide in air. The cell doubling time was approxi-
mately 12 h. For growth inhibition and cytotoxicity assays, cells
were adapted to grow in RPMI medium supplemented with 10%
(v/v) dialysed serum (dialysed for 24 h at 4°C against two changes
of 9 volumes of phosphate-buffered saline (PBS) containing 1 g
activated charcoal L–1 and a further two changes of 9 volumes
of PBS) to remove thymidine. Once transferred to medium
containing dialysed serum cells were passaged for at least 4 weeks
prior to cytotoxicity assays, when the cell doubling time was also
approximately 12 h. Cells were routinely tested to exclude
mycoplasma contamination (Chen, 1977).
Nucleoside transport inhibition assay
Thymidine uptake was assayed in L1210 cells using a modifica-
tion of the rapid mixing technique of Wohlheuter et al (1978). The
uptake of 100 mM thymidine by 106 cells was followed at 2-second
intervals over a 12-second time course in the presence or absence
of inhibitor in 1% or 5% (v/v) DMSO. In experiments to determine
the effect of AGP, the uptake of thymidine was also measured in
the presence of 5 mg ml–1 human AGP (Sigma), which is the upper
limit of plasma AGP concentrations in cancer patients, i.e. approx-
imately 125 mM (Kremer et al, 1988).
Exponentially growing L1210 cells were washed with and resus-
pended in ice-cold transport buffer (130 mM sodium chloride, 5
mM potassium chloride, 1 mM magnesium chloride, 5 mM
NaH2PO4, 10 mM glucose and 10 mM HEPES pH 7.4) at 2–4 ´ 107
cells ml–1. Cells were left on ice for 30 min prior to starting
the assay and then diluted further in transport buffer ± AGP
(7.5 mg ml–1) containing 1.5% or 7.5% (v/v) DMSO (± inhibitor at
1.5 ´ the final concentration) for 5 min at 21°C. The suspension
was mixed and 100 ml was layered onto 150 ml silicone oil (9:11
Dow Corning 556 (Sp.Gr. 0.98): Dow Corning 550 (Sp. Gr. 1.068),
final Sp. Gr. 1.028) overlaying 50 ml 3 M potassium hydroxide
(KOH), in six replicate 0.5 ml microfuge tubes. Transport was
initiated by adding 50 ml of 300 mM thymidine in transport buffer,
containing 25 mCi ml–1 [methyl-3H]thymidine (Sp. Act. 1.5–2.2
TBq mmol–1; Amersham, UK) and 2 mCi ml–1 [U-14C]sucrose
(17–27 GBq mmol–1; Amersham), to each tube in turn at 1-second
intervals, giving final concentrations of: 106 cells in transport
buffer± 5 mg ml–1 AGP, 100 mM thymidine and 1% or 5% (v/v)
DMSO± inhibitor. Transport was stopped by the addition of 50 ml
of400 mM dipyridamole at 1-second intervals to the tubes in reverse
order. The tubes were immediately centrifuged at 12 000g for
2 min at room temperature causing the cells to pass through the oil
and into the KOH. [14C]Sucrose, which does not enter cells with
intact plasma membranes, was included to allow calculation of the
amount of extracellular fluid passing through the oil, and hence the
amount of non-transported contaminating [3H]thymidine in the
extracellular space. Cell number and viability in each assay was
determined by haemocytometer counting using trypan blue exclu-
sion. After centrifugation the tubes were capped and cut in the oil
layer such that the bottom portion (cells solubilized in KOH) fell
into a 20 ml scintillation vial. One millilitre of 0.25 M acetic acid
was injected into the tube to disperse and neutralize the KOH-solu-
bilized cells and following the addition of 10 ml of Optiphase
HiSafe scintillant (Fischer Chemicals, Loughborough, UK) the
radioactivity in the cells was determined by a dual label assay
using an LKB-Wallac S1410 b-counter (Wallac (UK), Milton
Keynes, UK). The rate of thymidine uptake in the presence and
absence of inhibitor was calculated by unweighted linear regres-
sion analysis of thymidine uptake (pmol 10–6 cells) vs time
(seconds) using GraphPad PRISMTM software (GraphPad Software
Inc. San Diego, CA, USA).
Inhibition kinetics
Dipyridamole and NU3076 inhibition kinetics were investigated
by modifying the transport assay to measure the uptake of thymi-
dine at concentrations ranging from 100 to 1500 mM in the pres-
ence or absence of 0.3 mM dipyridamole or NU3076. Kt and Tmax
values were calculated using the equation describing a one-site
binding hyperbola, fitted using GraphPad PRISM software. The Ki
values for dipyridamole and NU3076 were determined by
measuring the uptake of 800 mM and 400 mM thymidine in the pres-
ence of increasing concentrations of inhibitor.
Table 2 Comparison of the potentiation of CB3717-induced growth
inhibition by NU3026, NU3059, NU3060 and dipyridamole in L1210 cells in
the presence or absence of thymidine
% Control cell growth % Control cell growth
± Nucleoside
+ 3 mM CB3717 + 10 mM CB3717
transport inhibitor no TdR + 1 mM TdR no TdR + 1 mM TdR
No inhibitor 40 104 5 107
10 mM Dipyridamole 4 4 0 1
10 mM NU3059 5 10 0 7
10 mM NU3026 8 26 1 20
10 mM NU3060 29 59 3 37
Cell growth was determined after 48 hour exposure to 3 mM or 10 mM CB3717
with or without 1 mM thymidine supplementation in the presence or absence
of 10 mM dipyridamole, NU3026, NU3059 or NU3060. Data, normalized by
comparison with cell growth in the presence of 10 mM dipyridamole, NU3026,
NU3059 or NU3060 alone, are the mean of three independent observations.
Standard deviations (not shown) were < 15% of the mean in each case.Potentiation of TS inhibitor toxicity by dipyridamole analogues 1741
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Growth inhibition assays
L1210 cells in exponential growth were dispensed into each well
of a 24-well plate at 104 cells ml–1, in RPMI-1640 medium supple-
mented with (10% v/v) dialysed serum containing CB3717, with
or without thymidine and/or transport inhibitor (4–6 replicate
wells for each drug combination). The DMSO concentration was
controlled so as to be present at 1% (v/v) in the final incubation.
Replicate aliquots of the remaining cell suspension were counted
to obtain a time zero cell count. After incubation at 37°C for 48 h
(to allow for a minimum of three control cell doublings) cells were
counted using a Coulter Counter Model Z1 (Coulter Electronics,
Luton, UK).
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Figure 1 Potentiation of CB3717 growth inhibition by dipyridamole and
selected analogues. Cell growth was determined after 48-h exposure to 3 mM
CB3717 with or without 1 mM thymidine supplementation in the presence or
absence of 10 mM dipyridamole, NU3026, NU3059 or NU3060. Data,
normalized by comparison with cell growth in the presence of 10 mM
dipyridamole, NU3026, NU3059 or NU3060 alone, are the mean of three
independent observations. Standard deviations (not shown) were < 15% in
every case
Figure 2 Nucleoside transport inhibition by dipyridamole and NU3076.
Thymidine uptake was measured in the absence of inhibitor (l, solid line),
and in the presence of 0.3 mM dipyridamole, (l l, dashed line) or 0.3 mM
NU3076 (s, dotted line). Lines were fitted as described in Materials and
Methods
Table 4 Kinetic constants for thymidine transport and inhibition by NU3076
and dipyridamole in L1210 cells
Kt Tmax Tmax/Kt
(mM) (pmol/10–6 (pmol/10–6
cells/s) cells/s/mM)
No inhibitor 202 ± 35 (5) 11 ± 1.1 (5) 0.05 ± 0.01 (5)
0.3 mM dipyridamole 268 ± 66 (5)a 8.4 ± 0.7 (5)b 0.03 ± 0.01 (5)b
0.3 mM NU3076 271 ± 61 (4)a 8.5 ± 0.8 (4)b 0.03 ± 0.004 (4)b
Figures are mean ± s.d. for the number of independent experiments given in
parenthesis. Significant difference from control (unpaired, two-tailed,
Student’s t-test) are given by: aP < 0.1; bP < 0.05.
Table 3 Inhibition of thymidine uptake by dipyridamole and NU3076 in the presence or absence of AGP
Dipyridamole NU3076
Structure
IC50 for thymidine uptake (mM) 0.36, 0.37 0.25 ± 0.08 (3)
Inhibitor concentration 1 mM 80 ± 8 (26)a 56 ± 10 (7)
1 mM + AGPb 4 ± 11 (9) 46 ± 7 (7)NS
10 mM 99 ± 2 (84) 96 ± 8 (18)
10 mM + AGP 13 ± 12 (27)c 89 ± 14 (9)NS
Figures are individual values or mean ± standard deviation with the number of observations given in parentheses. aData are the % inhibition of thymidine
uptake. bAGP concentration was 5 mg ml–1. cSignificantly different from value obtained in absence of AGP, P < 0.01 (unpaired Student’s t-test). NS, not
significantly different from value obtained in absence of AGP.1742 NJ Curtin et al
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Cytotoxicity assay
L1210 cells adapted to grow in dialysed serum were exposed to
varying concentrations of nolatrexed or 5-FU in the presence or
absence of 1 mM dipyridamole or 1 mM NU3076 for 16 h in
medium containing (10% v/v) dialysed serum. The cells were
resuspended in fresh medium to remove the drug, counted and
seeded for colony formation in 0.125% (w/v) agarose (SeaKem,
Flowgen, Sittingbourne, UK) in medium supplemented with 10%
(v/v) undialysed serum. To investigate prevention of thymidine
rescue, L1210 cells were incubated for 16 h with a fixed concen-
tration of nolatrexed (0, 10 or 100 mM), with or without 1 mM
thymidine, in the presence or absence of 1 mM dipyridamole or
NU3076, and then counted and seeded for colony formation in
0.125% (w/v) agarose as above. The enhancement factor EF90 was
calculated using the following equation:
EF90 = LC90 nolatrexed alone/LC90 nolatrexed + inhibitor
(where LC90 is the concentration of drug required to decrease cell
survival by 90%). The enhancement factor at 50% survival, EF50,
was calculated by substituting LC50 values in the above equation.
RESULTS
Dipyridamole analogues with modifications of the
diethanolamine side chains
Inhibition of thymidine uptake
The inhibition of thymidine uptake by three novel compounds
(NU3026, NU3059 and NU3060), with different substituents at the
2,6-position of the pyrimidopyrimidine ring was determined, and
inhibition at concentrations of 1 and 10 mM of these inhibitors, as
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Figure 4 Potentiation of nolatrexed cytotoxicity by 1 mM NU3076 and
dipyridamole. Cells were exposed to nolatrexed alone (•), or in the presence
of 1 mM NU3076 (s) or 1 mM dipyridamole (l l), for 16 h prior to seeding for
colony formation in drug-free medium containing 0.125% (w/v) agarose. Data
are mean ± s.d. of triplicate colony counts from each of the cell populations
exposed in duplicate, from a single representative experimentPotentiation of TS inhibitor toxicity by dipyridamole analogues 1743
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well as the IC50 values for inhibition of thymidine uptake, are
given in Table 1. All three compounds were less potent than
dipyridamole in the absence of AGP. However, in the presence
of 5 mg ml–1 AGP, dipyridamole was inactive as an inhibitor of
thymidine uptake, whereas all of the novel compounds retained
significant activity.
Potentiation of the growth inhibition produced by the TS
inhibitor, CB3717
The inhibition of the growth of L1210 cells by CB3717, with or
without 1 mM thymidine, determined in the presence or absence of
10 mM nucleoside transport inhibitor is shown in Figure 1. All the
inhibitors potentiated growth inhibition produced by 3 mM
CB3717 in the absence of salvageable thymidine, and also
prevented thymidine rescue from CB3717-induced growth inhibi-
tion. Comparable results were obtained by combining the transport
inhibitors with 10 mM CB3717 (Table 2). Similarly, there was a
modest potentiation of CB3717 growth inhibition by 1 mM dipyri-
damole, NU3059 and NU3026 and partial reversal of thymidine
rescue by 1 mM dipyridamole and NU3059 (data not shown). For
both potentiation of CB3717-induced growth inhibition and
prevention of thymidine rescue the rank order of potency of the
compounds was: dipyridamole > NU3059 > NU3026 > NU3060.
Comparison of the inhibitory effect of 10 mM inhibitor on nucleo-
side transport (Table 1) with the effect on cell growth (in the
presence of CB3717 + TdR) demonstrated a significant positive
rank correlation (Spearman’s rank correlation coefficient = 0.9,
P = 0.083).
A dipyridamole analogue modified at the 4,8-position
(NU3076)
Inhibition of thymidine uptake in the presence and absence
of AGP
In an attempt to identify a potent dipyridamole analogue
completely devoid of AGP binding, synthetic efforts were directed
at replacing the 4,8-piperidino group of dipyridamole with other
moieties. These modifications led to the identification of NU3076.
As shown in Table 3, NU3076 was at least as potent as dipyri-
damole and AGP (5 mg ml–1) did not significantly reduce the inhi-
bition of thymidine uptake at either 10 mM or 1 mM NU3076
(equivalent to a 12- and 120-fold molar excess of AGP respec-
tively). In contrast, AGP at this concentration abolished the inhibi-
tion of thymidine uptake by both 1 mM and 10 mM dipyridamole.
NU3076 was therefore selected for further investigation and
comparison with dipyridamole.
Table 5 Potentiation of nolatrexed and 5-FU cytotoxicity by dipyridamole
and NU3076
Cytotoxic Treatment LC50 mM LC90 mM EF50 EF90
agent
Nolatrexed Control 3.1 ± 1.9 22, 65
Nolatrexed 1 mM DP 2.5 ± 1.7 10 ± 6 1.3 ± 0.1a 7.5, 6.1
Nolatrexed 1 mM NU3076 2.1 ± 1.7 11 ± 3 1.6 ± 0.4a 2.7, 5.9
5-FU Control 3.7 ± 1.5 20 ± 10
5-FU 1 mM DP 3.4 ± 1.0 19 ± 6 1.3 ± 0.3 1.2 ± 0.1 
5-FU 1 mM NU3076 4.1 ± 1.6 17 ± 9 1.1 ± 0.1 1.3 ± 0.2a
The Enhancement Factors (EF) are the ratio of the LC50 or LC90 values for
nolatrexed or 5-FU in the presence and absence of dipyridamole or NU3076.
Results are expressed as individual values or mean ± s.d. of three
experiments. aIndicates a significant difference from control by paired, two-
tailed, Student’s t-test.
10 mM
Nolatrexed
125
100
75
50
25
0
S
u
r
v
i
v
a
l
 
(
%
 
c
o
n
t
r
o
l
)
10 mM Nolatrexed
+ 1mM Thymidine
Control
1 mM DP
1 mM NU3076
10 mM DP
Figure 5 Potentiation of 10 mM nolatrexed cytotoxicity and prevention of
thymidine rescue by NU3076 and dipyridamole. Cells were exposed to 10 mM
nolatrexed in the presence or absence of 1 mM thymidine (open bars), or 1 mM
thymidine with 1 mM NU3076 (solid bars), 1 mM dipyridamole (hatched bars) or
10 mM dipyridamole (cross-hatched bars) for 16 h prior to seeding for colony
formation in drug-free medium containing 0.125% (w/v) agarose. Data are
mean ± s.d., of triplicate colony counts from each of the cell populations
exposed in duplicate, from a single representative experiment
100.0
10.0
1.0
0.1
S
u
r
v
i
v
a
l
 
(
%
 
c
o
n
t
r
o
l
)
0 2 55 07 5 1 0 0
[5-FU] mM
Figure 6 Potentiation of 5-FU cytotoxicity by 1 mM NU3076 and
dipyridamole. Cells were exposed to 5-FU alone (•), or 5-FU in the presence
of 1 mM NU3076 (s) or 1 mM dipyridamole (l l) for 16 h prior to seeding for
colony formation in drug-free medium containing 0.125% (w/v) agarose. Data
are mean ± s.d. of triplicate colony counts from each of the cell populations
exposed in duplicate, from a single representative experiment1744 NJ Curtin et al
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Inhibition kinetics
Kinetic measurements were performed to determine the mecha-
nism responsible for the inhibition of thymidine uptake by dipyri-
damole and NU3076. The apparent Kt and  Tmax of nucleoside
transport in L1210 cells was calculated in the absence and in the
presence of 0.3 mM dipyridamole or 0.3 mM NU3076, Figure 2 and
Table 4. There was a significant decrease in the apparent Tmax for
thymidine transport in the presence of 0.3 mM dipyridamole and
NU3076 (P = 0.006 and P = 0.015 respectively). The apparent Kt
values were only marginally different from the control value
(P = 0.083 and 0.069 for 0.3 mM dipyridamole and NU3076
respectively). When compared to control values, a significant
decrease in the Tmax/Kt ratio was observed with both dipyridamole
and NU3076, indicative (together with a decrease in Tmax) of
mixed inhibition. The Ki values for dipyridamole and NU3076
were determined, using Dixon plots at thymidine concentrations of
400 and 800 mM, the Ki for dipyridamole and NU3076 were esti-
mated to be 0.28 mM and 0.1 mM respectively (Figure 3).
Potentiation of TS inhibitor cytotoxicity
Neither 1 mM NU3076 nor 1 mM dipyridamole were cytotoxic per
se against L1210 cells (cell survival ± standard error of 100 ± 24%
and 100 ± 19% respectively). The clonogenic survival of L1210
cells exposed to varying concentrations of nolatrexed in the
absence of thymidine, and in the presence or absence of 1 mM of
dipyridamole or NU3076 is shown in Figure 4, corresponding
LC50 and LC90 values are given in Table 5. NU3076 and dipyri-
damole at 1 mM produced equivalent potentiation of nolatrexed
cytotoxicity (Figure 4 and Table 5) and, as cells were exposed to
nolatrexed in medium supplemented with dialysed serum, potenti-
ation by dipyridamole and NU3076 was not due to the prevention
of thymidine rescue. Thymidine rescue from nolatrexed cytotoxi-
city in L1210 cells in the presence and absence of dipyridamole
and NU3076 was also investigated. The cytotoxic effect of 10 mM
nolatrexed was completely prevented by supplementing the
medium with 1 mM thymidine and both dipyridamole and NU3076
at 1 mM were equi-active in preventing thymidine rescue, which
was reduced but not blocked completely (Figure 5). In the pres-
ence of 10 mM dipyridamole thymidine rescue was completely
blocked; the survival of cells exposed to nolatrexed and thymidine
in the presence of 10 mM dipyridamole being equivalent to that of
cells exposed to nolatrexed alone (Figure 5). It was not possible to
investigate the prevention of thymidine rescue by 10 mM NU3076
due to the limited solubility of the analogue.
The effect of 1 mM dipyridamole or 1 mM NU3076 on the cytotox-
icity of 5-FU was also determined. A representative survival curve is
shown in Figure 6, and pooled LC50 and LC90 data (from three inde-
pendent experiments) are given in Table 5. Significant potentiation of
5-FU cytotoxicity by dipyridamole and NU3076 was observed at
high concentrations of 5-FU (30 mM and 100 mM) but at lower
concentrations the potentiation was not significant. NU3076 also
significantly reduced the IC90 concentration of FU. These experi-
ments were conducted in the absence of salvageable thymidine (dial-
ysed serum) and hence potentiation was presumably due to inhibition
of nucleoside efflux (deoxyuridine, fluorodeoxyuridine and/or fluo-
rouridine) although this was not determined experimentally.
DISCUSSION
Three dipyridamole analogues with altered 2,6-substituents
(NU3026, NU3059 and NU3060) have been identified which,
although less potent than dipyridamole in the absence of AGP, retain
significant activity in the presence of this plasma protein. The three
analogues were compared with dipyridamole as modulators of
CB3717-induced growth inhibition and, in the absence of salvageable
thymidine, all of the analogues increased the growth inhibitory effect
of CB3717. In the absence of thymidine the potentiation of CB3717
activity was probably due to the inhibition of deoxuridine efflux,
which has been shown in the case of dipyridamole to result in greater
dUTP accumulation and DNA strand breakage (Curtin et al, 1991).
All three dipyridamole analogues were also able to block thymidine
rescue from CB3717-induced growth inhibition to a degree that was
related to their potencies as inhibitors of nucleoside transport.
Substitution of the 4,8-piperidino groups of dipyridamole with a
p-methoxybenzylamino group, as in the case of NU3076, resulted in
both improved potency as a nucleoside transport inhibitor and
reduced susceptibility to AGP binding. Notably, the activity of
NU3076 was not significantly affected by a > 100-fold molar excess
of AGP whereas the activity of dipyridamole was abolished under
equivalent conditions. The kinetic parameters calculated in this
study for thymidine uptake by L1210 cells, and the Ki for dipyri-
damole are comparable to reported values (Plagemann and
Wohlhueter, 1984). Both dipyridamole and NU3076 were found to
exhibit mixed-type inhibition, indicating that the interaction with the
nucleoside transporter is more complex than simple competition
between dipyridamole and nucleosides for the substrate binding site,
again in agreement with previous observations (Woffendin and
Plagemann, 1987). Dipyridamole-sensitive nucleoside transport is
mediated by equilibrative transporters, of which there are two sub-
types (es and ei) which exhibit different kinetic properties (Jarvis,
1986; Plagemann et al, 1988; Hammond, 1991) and are the product
of distinct genes (Griffiths et al, 1997; Crawford et al, 1998). The
proportion of carriers expressed in the L1210 cells used in these
studies was found to be about 70% es, and 30% ei (K Bowman,
unpublished data), in agreement with published data (Belt, 1983).
The affinity of dipyridamole for the es transporter is probably 2.5 ´
higher than for the ei transporter (Hammond, 1991), producing
different inhibition constants for each transporter subtype. Thus, the
mixed-type inhibition of thymidine uptake observed with dipyri-
damole and NU3076 in L1210 cells may reflect the presence of the
two different transporter proteins.
Both nolatrexed and 5-FU were cytotoxic to L1210 cells in a
concentration-dependent manner. The observation that 1 mM
thymidine completely reversed the cytotoxic effects of nolatrexed
in L1210 cells confirms that TS is the locus of action of the drug in
these cells, as has been demonstrated in other cell lines (Webber
et al, 1996). Cell survival decreased in response to increasing
concentrations of nolatrexed, with only 10–20% of cells surviving
exposure to 10 mM nolatrexed. At concentrations above 10 mM
nolatrexed there was very little further increase in cytotoxicity,
suggesting a fraction of the cells are resistant to inhibition of TS,
probably because they failed to enter a nolatrexed-sensitive phase
of the cell cycle during the period of drug exposure. Cell killing
also increased in response to increasing 5-FU concentrations;
however, in contrast to the pattern of cytotoxicity of nolatrexed,
there was no apparent plateau in cell survival. The lack of a resis-
tant fraction of cells may reflect the fact that 5-FU has a number of
loci of action in addition to TS inhibition, e.g. FUTP and FdUTP
incorporation into RNA and DNA respectively.
Both dipyridamole and the novel analogue NU3076 were
approximately equipotent as enhancers of the cytotoxicity of nola-
trexed and 5-FU and, since the clonogenic cell survival studiesPotentiation of TS inhibitor toxicity by dipyridamole analogues 1745
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were carried out in medium supplemented with dialysed serum,
potentiation by dipyridamole and NU3076 was not due to inhibi-
tion of thymidine rescue. By analogy with previous studies (Grem
and Fischer 1985, 1989; Curtin et al, 1988, 1991) potentiation in
the absence of thymidine is most likely to be due to inhibition of
nucleoside efflux (deoxuridine, fluorodeoxuridine, fluorouridine)
leading to greater accumulation of cytotoxic nucleosides.
Modulation of thymidine rescue from nolatrexed cytotoxicity by
dipyridamole and NU3076 was also investigated, and the
complete reversal of nolatrexed cytotoxicity by 1 mM thymidine
was partially inhibited by both 1 mM dipyridamole and NU3076,
and completely blocked by 10 mM dipyridamole. In nucleoside
transport assays thymidine uptake was inhibited by 80% at 1 mM
dipyridamole and by 56% at 1 mM NU3076, consistent with the
partial rescue from nolatrexed cytotoxicity at this concentration. In
the presence of 10 mM dipyridamole, which produced 99% inhibi-
tion of thymidine uptake in transport studies, thymidine rescue
was completely blocked such that the survival of cells exposed to
nolatrexed, thymidine and 10 mM dipyridamole was not signifi-
cantly different from that of cells exposed to nolatrexed alone. It
was not possible to investigate the prevention of thymidine rescue
by 10 mM NU3076 due to the limited solubility of this compound.
Recent data from this laboratory (P Smith, manuscript in prepara-
tion) indicate that NU3076 can block thymidine rescue from TS
inhibitor cytotoxicity in human cancer cell lines.
Both dipyridamole and NU3076 potentiated 5-FU cytotoxicity
to a similar extent. However, potentiation was only apparent at
high concentrations of 5-FU, and the degree of potentiation of
5-FU was less than that observed for nolatrexed. In other studies
dipyridamole has been shown to potentiate 5-FU cytotoxicity by
different mechanisms in different cell lines. In WiDr human colon
adenocarcinoma cells, dipyridamole potentiated 5-FU cytotoxicity
by depletion of cellular dTTP pools (Lonn et al, 1989). In HCT
116 cells, the potentiation of 5-FU by dipyridamole was con-
sidered to be a consequence of both elevated dUMP levels and
increased intracellular accumulation of FdUMP, the latter formed
from FUdR. These nucleotide pool changes were thought to reflect
the combined effects of de-repression of dCMP deaminase and
thymidine kinase, following loss of feedback inhibition by dTTP,
and inhibition of deoxyuridine and fluorodeoxuridine efflux
(Grem and Fisher, 1985, 1989). An investigation into which of
these mechanisms is critical to 5-FU cytotoxicity in L1210 cells
has not been undertaken, but clearly TS inhibition is not the only
important locus of action of the drug.
From the data reported here it is apparent that AGP binding,
which has limited the clinical use of dipyridamole as an enhancer
of antimetabolite chemotherapy, can be overcome. Potentiation of
the growth inhibition and cytotoxicity of TS inhibitors by novel
dipyridamole analogues was related to nucleoside transport
inhibitory potency. All of the compounds described here were
more potent than dipyridamole in the presence of physiological
concentrations of AGP, and the potency of one compound,
NU3076, was not significantly affected by AGP binding.
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